Story

Valneva Stock Slides After Widened Loss and Lowered 2026 Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 13, 20261 min read
Valneva Stock Slides After Widened Loss and Lowered 2026 Guidance
Text size
Background

Shares of Valneva (VLS) declined Tuesday after the French specialty vaccine maker announced a wider net loss for the first half of 2026 and trimmed its full-year financial guidance. The company cited weaker demand for travel vaccines and one-off charges for the disappointing results.

Disappointing H1 Financials

Valneva reported a net loss of €63.3 million for the first half of the year, a substantial deterioration from the €20.8 million net loss recorded in the first half of 2025. The company also posted a drop in its revenue and operating profit for the period.

According to the release, the wider loss was driven by several factors:

  • Lower gross margins and reduced sales volumes for its travel vaccines.
  • One-off charges, including costs from a contract termination related to its IXCHIQ chikungunya vaccine.
  • Inventory write-offs.

Full-Year Outlook Trimmed

Sample IUX Markets – In-articleAd

Citing an adverse trend in travel vaccine uptake linked to geopolitical factors, Valneva lowered its financial forecast for the full year 2026. The company now expects product sales of €135 million to €150 million, down from its prior range of €145 million to €160 million.

Consequently, the forecast for total annual revenues was also reduced to between €145 million and €160 million, from a previous guidance of €155 million to €170 million.

Market Context and Analyst View

The stock's decline was amplified by a classic "sell the news" reaction from investors. Valneva shares had surged roughly 9% in the two sessions immediately preceding the report, leaving the stock vulnerable to profit-taking on the downbeat results.

Analysts at broker Kempen noted that the market's reaction was broadly in line with consensus expectations. The firm reiterated that the key catalyst for Valneva remains the progress of its Lyme disease vaccine program, which is being developed in partnership with Pfizer.

Read next

More on Stocks
Back to latest news

LATEST